Forecasting The Future: 4 Analyst Projections For Amylyx Pharma
Portfolio Pulse from Benzinga Insights
Four analysts have recently shared their views on Amylyx Pharma (NASDAQ:AMLX), with ratings ranging from bullish to somewhat bullish. The average 12-month price target is now $33.00, down from $36.50, indicating a 9.59% decrease. Amylyx Pharma has shown significant revenue growth of 395.54% as of December 31, 2023, and outperforms in net margin, ROE, and ROA, with a low debt-to-equity ratio.
March 08, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Analysts have mixed views on AMLX, with a decreased average price target of $33.00. The company has shown impressive revenue growth and financial metrics.
The mixed analyst ratings with a slight decrease in the average price target suggest uncertainty, but the company's strong revenue growth and solid financial performance indicators like net margin, ROE, and ROA, along with a low debt-to-equity ratio, could counterbalance the impact on the stock price in the short term. The overall impact is neutral due to these opposing factors.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100